Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1435635

Generating advanced CAR-based therapy for hematological malignancies in clinical practice: Targets to cell sources to combinational strategies

Provisionally accepted
Shu Zhou Shu Zhou 1*Yuhang Yang Yuhang Yang 2Yulu Jing Yulu Jing 3Xiaoying Zhu Xiaoying Zhu 4*
  • 1 Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China
  • 2 Renmin Hospital of Wuhan University, Wuhan, China
  • 3 Zhongnan Hospital, Wuhan University, Wuhan, China
  • 4 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

The final, formatted version of the article will be published soon.

    Chimeric antigen receptor T (CAR-T) cell therapy has been a milestone breakthrough in the treatment of hematological malignancies, offering an effective therapeutic option for multi-line therapy-refractory patients. So far, abundant CAR-T products have been approved by the United States Food and Drug Administration or China National Medical Products Administration to treat relapsed or refractory hematological malignancies and exhibited unprecedented clinical efficiency. However, there were still several significant unmet need to be progressed, such as the life-threatening toxicities, the high cost, the labor-intensive manufacturing process and the poor long-term therapeutic efficacy. According to the demands, many researches, relating to notable technical progress and the replenishment of alternative targets or cells, have been performed with promising results. In this review, we will summarize the current research progress in CAR-T eras from the "targets" to "alternative cells", to "combinational drugs" in preclinical studies and clinical trials.

    Keywords: Chimeric antigen receptor T cell, hematological malignancies, targets, Allogeneic, Combinatorial therapy

    Received: 20 May 2024; Accepted: 03 Sep 2024.

    Copyright: © 2024 Zhou, Yang, Jing and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shu Zhou, Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China
    Xiaoying Zhu, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.